Tuesday, May 7, 2024 | 1:30 PM - 2:15 PM PDT

Which Biotechs Will Big Pharma Buy Next on Their Shopping Spree?

Big Pharma is on a major shopping spree. Both AbbVie (ABBV) and Merck & Co. (MRK) have been very active on the M&A front, buying promising biotechs for 75% to 100% overnight premiums. Blockbuster drugs like Merck’s Keytruda, with $25 billion in annual sales, lose patent protection in 2028. Since biotech M&A is the best way to refill the pipeline, the transaction train should keep on rolling. Find out from John which companies look the most attractive for investors in this informative briefing.     

John McCamant
Editor
Medical Technology Stock Letter

Get the Keys to Market Success in 2024